Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2509 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorised share capital at the end of the month and provides details on issued shares and public float sufficiency. The report indicates that the public float requirement has been complied with as of the end of the reporting period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Qyuns Therapeutics Co., Ltd. on 6ix
Earlier from Qyuns Therapeutics
- Voluntary announcement phase III clinical study results of Oturkibart (QX005N) for treatment of prurigo nodularis presented as a late-breaking oral presentation at EADV 2026
- List of directors and their roles and functions
- Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; and resignation and proposed appointment of non-executive director
- 2026 Interim report
- A Decade of Persistent Steps, Aspiring for a Thousand Miles: Qyuns' Grand 10th Anniversary Celebration Held Successfully
Later from Qyuns Therapeutics
- Announcement book closure period for extraordinary general meeting
- (1) Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; (2) proposed appointment of director and determination of the director's remuneration; and (3) notice of the 2026 first extraordinary general meeting
- Notice of the 2026 first extraordinary general meeting
- Form of proxy for the extraordinary general meeting to be held on Friday, November 13, 2026
- Documents on Display
Follow Qyuns Therapeutics into a list and get an email when it puts out news.
Follow Qyuns Therapeutics